LinkedIn is a social media tool I find greatly flawed, but useful. Part of the devil's pact one makes with LinkedIn is to receive great amounts of requests from individuals who wish to grow their networks. I have a personal guideline for such which help me weed through the requests, but last year I got a request that had me laughing -- and slightly revising that guideline.
A computational biologist's personal views on new technologies & publications on genomics & proteomics and their impact on drug discovery
Monday, January 19, 2015
Sunday, January 18, 2015
In this final installment of a series of reactions to news coming from the J.P. Morgan Conference, I'll cover an interesting complementary technology that was announced. But first, it might appear my prediction of no radical sequencer announcements may have been invalidated, with an announcement from BGI of plans to launch two sequencers based on Complete Genomic's technology. Unfortunately, the only outlet that seems to have covered this is GenomeWeb, and it is in their premium (paywalled) section, so I know nothing beyond that. It appears this was only announced around JPM and not at JPM, so I have a Clintonesque out as well.
Wednesday, January 14, 2015
Illumina's Expanded Lineup
In my JP Morgan predictions for sequencing platforms, I didn't do badly. The only major player to make a platform announcement was Illumina, and they did indeed announce instruments that are not radical departures from the prior platforms. I am kicking myself for not making more specific predictions, as the nature of the new boxes was really unsurprising and it would have been nice to nail that.
Monday, January 12, 2015
2015: Another Year of Sequencing Evolution (not Revolution)?
The J.P. Morgan Conference is firing up, and for the past few years that has meant big sequencing platform announcements -- HiSeq or Ion Proton or such. This has stolen some of the thunder from AGBT in terms of major announcements (sadly, I won't be attending this year -- and will try not to land my self into surgery the way I did the last time I didn't attend AGBT). I figured I'd better write this tonight before any more JPM-related sequencing instrument announcements show up, or more to my prediction, before the conference ends without any.
Subscribe to: Posts (Atom)